Economic Model For Antibiotics Is Broken, AstraZeneca’s Rex Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A better economic model for anti-infective research would include incentives to start antibiotic R&D, AstraZeneca exec John Rex tells ICAAC, and go beyond current initiatives that provide financial relief after a new antibiotic is developed.